Concepedia

Michiko Hanazono

MH

Statistics

Publications

3

Citations

37

H-Index

3

Active since

2019

Affiliations

Chiba University(Current)

Chiba Cancer Center

Tokyo Women's Medical University

Toho University

Michiko Hanazono is an author at Chiba University specializing in oncology, cancer cell signaling, and medicine.

Publications per year

2019–2021

3

Publications

3

AMPK activation induced in pemetrexed‐treated cells is associated with development of drug resistance independently of target enzyme expression

Yiyang Qin, Ikuo Sekine, Michiko Hanazono et al. · Molecular Oncology · 2019 · 16 citations · Full text

, , +16

A p53-stabilizing agent, CP-31398, induces p21 expression with increased G2/M phase through the YY1 transcription factor in esophageal carcinoma defective of the p53 pathway.

Boya Zhong, Masato Shingyoji, Michiko Hanazono et al. · PubMed · 2019 · 11 citations · Full text

, , +17

An MDM2 inhibitor achieves synergistic cytotoxic effects with adenoviruses lacking E1B55kDa gene on mesothelioma with the wild-type p53 through augmenting NFI expression

Thao Thi Thanh Nguyen, Masato Shingyoji, Michiko Hanazono et al. · Cell Death and Disease · 2021 · 10 citations · Full text

, , +17

1–3 of 3